LYEL vs MAIA

Lyell Immunopharma, Inc. vs MAIA Biotechnology, Inc. — Valuation Comparison 2026

LYEL

Biotechnology
Lyell Immunopharma, Inc.
Quality
4.8
out of 10
Value Trap
32
LOW
Price
$16.83
Last close
Models
9/13
Active
VS

MAIA

Biotechnology
MAIA Biotechnology, Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$1.29
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType LYEL Fair ValueLYEL Upside MAIA Fair ValueMAIA Upside
Bayesian DCF Intrinsic $4.48 -73.4% $0.65 -49.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.03 -85.4% $0.28 -78.1%
Dynamic NAV Asset-Based $14.95 -11.2% $0.53 -58.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for LYEL vs MAIA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LYEL vs MAIA — Which Stock Is More Undervalued?

LYEL scores higher with a 4.8/10 quality rating vs MAIA's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lyell Immunopharma, Inc. (LYEL) and MAIA Biotechnology, Inc. (MAIA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LYEL currently trades at $16.83 with a QOC of 4.8/10, while MAIA trades at $1.29 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).